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Aims Experimental autoimmune myocarditis (EAM) model mirrors important mechanisms of inflammatory dilated cardio-
myopathy (iDCM). In EAM, inflammatory CD133+ progenitors are a major cellular source of cardiac myofibroblasts
in the post-inflammatory myocardium. We hypothesized that exogenous delivery of macrophage-colony-stimulating
factor (M-CSF) can stimulate macrophage lineage differentiation of inflammatory progenitors and, therefore, prevent
their naturally occurring myofibroblast fate in EAM.
Methods
and results
EAM was induced in wild-type (BALB/c) and nitric oxide synthase 2-deficient (Nos22/2) mice and CD133+ progeni-
tors were isolated from inflamed hearts. In vitro, M-CSF converted inflammatory CD133+ progenitors into nitric
oxide-producing F4/80+ macrophages and prevented transforming growth factor-b-mediated myofibroblast differen-
tiation. Importantly, only a subset of heart-infiltrating CD133+ progenitors expresses macrophage-specific antigen F4/
80 in EAM. These CD133+/F4/80hi cells show impaired myofibrogenic potential compared with CD133+/F4/802
cells. M-CSF treatment of wild-type mice with EAM at the peak of disease markedly increased CD133+/F4/80hi
cells in the myocardium, and CD133+ progenitors isolated from M-CSF-treated mice failed to differentiate into myo-
fibroblasts. In contrast, M-CSF was not effective in converting CD133+ progenitors from inflamed hearts of Nos22/2
mice into macrophages, and M-CSF treatment did not result in increased CD133+/F4/80hi cell population in hearts of
Nos22/2 mice. Accordingly, M-CSF prevented post-inflammatory fibrosis and left ventricular dysfunction in wild-type
but not in Nos22/2 mice.
Conclusion Active and NOS2-dependent induction of macrophage lineage differentiation abrogates the myofibrogenic potential
of heart-infiltrating CD133+ progenitors. Modulating the in vivo differentiation fate of specific progenitors might
become a novel approach for the treatment of inflammatory heart diseases.
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1. Introduction
Inflammatory dilated cardiomyopathy (iDCM) is an important cause of
heart failure and sudden death in children and young patients.1 Pro-
gressive cardiac dilation and fibrosis are hallmarks of iDCM in
humans. iDCM refers to an end-stage heart failure phenotype that
often results from virus-triggered myocarditis.2 Both clinical observa-
tions and animal experiments suggest that infection-triggered auto-
immunity plays an important role in iDCM.3 Heart-specific
autoimmune responses are a consequence of the lack of T cell toler-
ance to heart-specific alpha-myosin heavy chain (aMyHC) in mice and
in humans.4
Experimental autoimmune myocarditis (EAM) is a CD4+ T cell-
mediated mouse model of iDCM. In susceptible mouse strains, EAM
is commonly induced after immunization with aMyHC peptide to-
gether with a strong adjuvant.4 In BALB/c mice, the extent of
cardiac infiltrates peaks 3 weeks after immunization. Inflammatory
infiltrates largely resolve thereafter, but the process of pathological
remodelling continues and many mice develop an end-stage heart
failure phenotype, including ventricular dilation, myocardial fibrosis,
and heart failure on follow-up.5
At the peak of EAM, inflammatory cells, including granulocytes,
monocytes, macrophages, T cells, B cells, and CD133+ progenitors,
infiltrate the myocardium.4,6 CD133 (prominin-1) and its human
orthologue, AC133, are often expressed on primitive cell populations
including haematopoietic stem cells. In EAM, bone marrow-derived
CD133+ progenitors represent the major cellular source of collagen-
producing fibroblasts involved in the progressive transforming growth
factor-beta (TGF-b)-mediated cardiac remodelling,6 which reflects
the transition from acute inflammation into the typical end-stage
heart failure phenotype.
Macrophages represent another important heart-infiltrating cell
subset in EAM7. In mice, macrophages commonly express the F4/80
antigen. Their role in disease pathogenesis, however, remains contro-
versial. So far, the nitric oxide synthase 2 (NOS2)-expressing M1
macrophage subset had been considered to contribute to disease
progression,7,8 On the other hand, nitric oxide also acts as a strong
immunosuppressive molecule preventing EAM development via in-
duction of T cell apoptosis.6 Alternatively, activated M2 macrophages
are considered to promote resolution of inflammation and reduce
disease severity.7– 9
Macrophage-colony-stimulating factor (M-CSF) is one of the key
cytokines regulating immune responses and reparative processes in
many inflammatory and cardiovascular disorders.10,11 M-CSF plays a
pivotal role in differentiation and maturation of the macrophage
myeloid lineage.12 Mice lacking functional M-CSF show macrophage
deficiency, reduced phagocytosis, and strongly impaired nitric oxide
production.13 In animal models of ischaemic heart failure and viral
myocarditis, M-CSF treatment improves cardiac function,14– 16 but
the mechanism is still unclear.
We hypothesize that altering the in vivo fate of inflammatory pro-
genitors by selectively promoting macrophage lineage differentiation
may protect from myofibroblast accumulation and cardiac fibrosis
in EAM. In fact, M-CSF-induced conversion of heart-infiltrating
CD133+ progenitors into F4/80+ macrophages and prevented their
myofibroblast differentiation in the post-inflammatory phase of
EAM. Moreover, our data points to critical role of NOS2 and nitric
oxide in M-CSF-dependent macrophage lineage differentiation of
inflammatory CD133+ progenitors. Thus, we demonstrate how
exogenous cytokine treatments may change the default differentiation
fate of inflammatory progenitors and can prevent pathological tissue
remodelling in iDCM.
2. Methods
2.1 Mice
BALB/c (n ¼ 250) and Nos22/2 (n ¼ 50) mice on BALB/c background
were used in this study. Animal experiments were performed in accord-
ance with the Swiss federal law and with the Guide for the Care and Use of
Laboratory Animals published by the US National Institutes of Health (NIH
Publication, 8th Edition, 2011). All animal experiments were approved by
the Cantonal Veterinary Office in Zu¨rich.
2.2 EAM induction and cytokine treatments
Mice were injected subcutaneously with 150 mg of aMyHC
(Ac-RSLKLMATLFSTYASADR-OH; Caslo) peptide emulsified 1:1 with
Complete Freund’s Adjuvant (CFA, Difco) on Days 0 and 7. M-CSF
200 mg/kg (Peprotech) was iv injected 5× every second day between
Days 21–29 or Days 40–48 of EAM. Control mice received solvent only.
2.3 Histopathology and immunocytochemistry
Hearts were formalin-fixed and paraffin embedded. Heart sections were
stained with rat anti-mouse CD45 (BD Bioscience), rabbit anti-mouse
CD3 (Neomarkers), rat anti-mouse F4/80 (BMA biomedicals) and rabbit
anti-rat IgG (Abcam) antibodies, and with the Bond Polymer Refine De-
tection kit using the BOND-MAX system (both Leica). Masson’s Trichrom
staining was used to detect fibrosis. Immunopositive cells and fibrotic
areas were quantified using analysis FIVE software (Olympus).
2.4 Echocardiography
Mice were lightly anaesthetized with 1–1.5% isoflurane, maintaining the
heart rate at 400–500 b.p.m.
Transthoracic echocardiography was performed using a 30 MHz probe
and the Vevo 770 Ultrasound system (VisualSonics) as described17 and in
Supplementary Material online.
2.5 Cell cultures
Myocarditis-positive hearts were perfused, dissected, and digested with
Liberase Blendzyme (Roche) for 45 min at 378C and tissue suspensions
were passed sequentially through 70 and 40 mm cell strainers. Cardio-
myocytes were separated by low speed centrifugation (50 g, 2 min).
CD133+ cells were isolated by positive selection using anti-CD133-PE
antibody (eBioscience) and magnetic anti-PE-microbeads (Miltenyi) or
using FACS. Enriched CD133+ cells were plated onto gelatine-coated
cell culture plates and cultured in the Iscove’s Modified Dulbecco’s
Medium supplemented with 20% foetal bovine serum, 1:100 penicillin/
streptomycin, 100 mM non-essential amino acids, 100 mM sodium
pyruvate, and 50 mM b-mercaptoethanol (all Invitrogen). Macrophage dif-
ferentiation was induced with 10 ng/mL M-CSF, and fibroblast differenti-
ation with 10 ng/mL TGF-b (both PeproTech).
2.6 Flow cytometry and cell sorting
Single cell suspensions were prepared from digested hearts and cultured
cells. Cells were incubated 30 min on ice with the appropriate combin-
ation of fluorochrome- or biotin-conjugated antibodies. The following
antibodies were used: anti-CD45-FITC, anti-CD45-PE, anti-NOS2-FITC
(all BD Bioscience), anti-CD133-PE, anti-F4/80-PE (both eBioscience),
biotin-conjugated anti-F4/80 (Cedarlane), anti-CD16/32 (Miltenyi),
anti-CD206 (Biolegend), anti-CD301 (Serotec), and anti-CD133
(eBioscience). Streptavidin-APC (BD Bioscience) was used to detect
biotin-conjugated antibodies. Cells were analysed with the FACSCanto
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analyser (BD Bioscience) and FlowJo software (Tree Star). In some experi-
ments, cells were sorted with FACSAria III (BD Bioscience).
2.7 Quantitative RT–PCR
Total RNA was isolated using the RNeasy micro kit (Qiagen). cDNAs
were amplified using the Power SYBR Green PCR Master Mix (Applied
Biosystems) and oligonucleotides complementary to transcripts of the
analysed genes using the 7500 Fast Real-Time PCR System (Applied Bio-
systems). The following oligonucleotides were used in this study: aSMA
(Acta2): 5′-cgctgtcaggaaccctgaga-3′, 5′-cgaagccggccttacaga-3′; collagen I
(Col1a1): 5′-gatgacgtgcaatgcaatgaa-3′, 5′-ccctcgactcctacatcttctga-3′; fibro-
nectin (Fn1): 5′-taccaaggtcaatccacacccc-3′, 5′-cagatggcaaaagaaagcagagg-3′ ;
gapdh (Gapdh): 5′-ctgcaccaccaactgcttagc-3′, 5′-ggcatggactgtggtcatgag-3′ .
Transcript levels of gapdh were used as an endogenous reference, and
relative gene expression was analysed using the 22DDCt method.
2.8 Immunohistochemistry and phagocytosis
assays
Cells were cultured on gelatine-coated cover slips and fixed with 4% par-
aformaldehyde or methanol:acetone (7:3). One per cent bovine serum
albumin was used as blocking solution. The following antibodies were
used: mouse IgG anti-aSMA (Sigma), rabbit IgG anti-fibronectin (Milipore),
AlexaFluor488 anti-mouse IgG, and AlexaFluor546 anti-rabbit IgG 1:600
(both Invitrogen). 4′,6-diamidino-2-phenylindole was used to label nuclei.
Alexa Fluor 488-conjugated Escherichia coli BioParticles (Invitrogen) were
used according to manufacturer’s recommendations. Immunofluorescence
was analysed using the Olympus BX51 fluorescence microscope.
2.9 Statistics
Normally distributed data were analysed by the unpaired, two-tailed Stu-
dent’s t-test, and by one-way ANOVA followed by the Bonferroni post hoc
test. Severity scores were analysed by the one-way Kruskal–Wallis ana-
lysis. For correlation analysis, Pearson’s correlation coefficient was calcu-
lated. All analyses were computed using the GraphPad Prism 5 software.
Differences were considered as statistically significant for P, 0.05.
3. Results
3.1 M-CSF converts heart-infiltrating
CD1331 progenitors into functional F4/801
macrophages, and prevents TGF-b-induced
myofibroblast differentiation in vitro
BALB/c mice receiving two subcutaneous injections of aMyHC/CFA
at Days 0 and 7 develop severe myocarditis at Day 21. At this
stage, CD133+ progenitors represent 30% of all CD45+ inflamma-
tory cells in the heart6. To assess the differentiation capacity of these
cells at the peak of disease, CD133+ cells were isolated from diseased
hearts at Day 21 of EAM, plated, and expanded for 2 weeks in vitro.
Expanded cells were cultured in the presence or absence of M-CSF
or TGF-b for additional 14 days. In the presence of TGF-b,
CD133+ cells differentiated into myofibroblasts, positive for aSMA
and fibronectin (Figure 1A and B). In contrast, the addition of M-CSF
failed to trigger myofibroblast differentiation (Figure 1A and B) and
pre-treatment of CD133+ cells with M-CSF for 3 days prevented
TGF-b-triggered myofibroblast formation (Figure 1C and D).
In cytokine-free cultures, most expanded cells remained positive
for CD133 and were mainly negative for macrophage marker F4/80
(Supplementary material online, Figure S1A and B). In the presence
of M-CSF, however, CD133 expression was reduced (Supplementary
material online, Figure S1A) and cells up-regulated F4/80, CD11b, and
CD16/32, suggesting macrophage lineage differentiation (Supplemen-
tary material online, Figure S1B–D). Cells cultured with M-CSF devel-
oped into fully active macrophages producing NOS2, secreting nitric
oxide, and phagocyting E.coli bacteria (Supplementary material
online, Figure S1E, F, and J). Of note, M-CSF treatment did not affect
expression of markers characteristic for alternatively activated M2
macrophages (CD206, CD301, Supplementary material online,
Figure S1G–H) or markers characteristic for granulocytes or dendritic
cells, i.e. Gr-1 (Ly6C, Supplementary material online, Figure S1I), MHC
class II and CD11c (not shown).
To address the immunomodulating potential of CD133+ progeni-
tors and CD133+-derived M-CSF-differentiated macrophages, we
co-cultured them with aMyHC-reactive Th17 cell lines in the pres-
ence of aMyHC-pulsed irradiated splenocytes as antigen presenting
cells. On irradiated splenocytes, aMyHC-reactive CD4+ T cells
proliferated rapidly. In the presence of CD133+ progenitors or M--
CSF-differentiated macrophages, however, proliferation was com-
pletely abolished (Supplementary material online, Figure S2A).
Further, we induced EAM in BALB/c mice and additionally admini-
strated iv 2 × 106 of either in vitro expanded CD133+ progenitors
or CD133+-derived mature macrophages at Day 7 after EAM induc-
tion and analysed myocarditis severity at Day 21. In animals treated
with both CD133+ progenitors and M-CSF-differentiated macro-
phages, practically no myocarditis was observed compared with
sham-treated mice (Supplementary material online, Figure S2B). In
contrast, the administration of M-CSF-differentiated macrophages
expanded from Nos22/2 mice failed to protect from myocarditis
(Supplementary material online, Figure S2C). These latter findings
confirm the protective and NOS2-dependent role of CD133+-
derived M-CSF-differentiated macrophages in EAM.
3.2 M-CSF treatment promotes
accumulation of F4/801 macrophages
in the post-inflammatory heart
At Day 21, inflamed hearts contained a substantial pool of CD133+
progenitors, but fibrosis was not evident at this time point. As illu-
strated above, M-CSF effectively directs CD133+ progenitors into
functional macrophages and prevents their myofibroblast differenti-
ation. We, therefore, analysed how systemic M-CSF treatment of
aMyHC/CFA-immunized mice affects the pattern of heart-infiltrating
cell subsets. Accordingly, aMyHC/CFA-immunized mice received
M-CSF injections between Days 21 and 29 of EAM (Supplementary
material online, Figure S3A). Three days after the first M-CSF injection,
we observed significantly increased number of F4/80+ and CD133+
cells in the myocardium of M-CSF-treated mice (Day 24, Figure 2A
and B). Immunopositive F4/80+ macrophages in the myocardium
decreased over time and remained at low numbers at Day 40
(Figure 2A; Supplementary material online, Figure S4A and B). M-CSF
treatments, however, did not affect the expression of CD16/32,
CD206, and CD301 in inflammatory macrophages (Figure 2E–G).
Instead, we observed significantly increased NOS2 on F4/80+ cells
in the heart after M-CSF treatment of wild-type mice (Figure 2D).
3.3 M-CSF inhibits formation
of myofibroblasts from inflammatory
CD1331 progenitors in EAM
Heart-infiltrating CD133+ progenitors represent the major cellular
source of myofibroblasts in post-inflammatory EAM.6 At Day 24 of
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EAM, we sorted inflammatory (CD45-positive) CD133+/F4/802 and
CD133+/F4/80hi cells from the inflamed myocardium of BALB/c
mice and found elevated levels of myofibroblast-specific genes in
CD133+ cells negative for F4/80 (Figure 3A and B). These findings
suggest that CD133+/F4/802 rather than CD133+/F4/80hi cells con-
tribute to fibrogenesis in post-inflammatory EAM.
M-CSF-stimulated CD133+ progenitors acquired a functional
macrophage phenotype within 3 days in vitro (Figure 2H). We, there-
fore, analysed F4/80 expression on heart-infiltrating CD133+ progeni-
tors in M-CSF-treated mice. We found that heart-infiltrating CD133+/
CD45+ cells of M-CSF-treated mice had higher expression of F4/80 at
Day 24 (i.e. 3 days after the cytokine treatment, Figure 3C and D).
Figure 1 M-CSF prevents differentiation of heart-infiltrating CD133+ progenitors into myofibroblasts. (A and B) Heart-infiltrating CD133+ cells
were expanded from myocarditis-positive hearts at Day 21 of EAM and stimulated without (control, white) or with 10 ng/mL M-CSF (grey), or
10 ng/mL TGF-b (black) for 14 days. Relative mRNA expression of myofibroblast-specific fibronectin (Fn1), collagen I (Col1a1), and aSMA (Acta2)
(A, n ¼ 5). Representative immunofluorescence and quantification analysis of aSMA (top) and fibronectin (bottom) in cultured cells (B, n ¼ 5).
(C and D) Expanded heart-infiltrating CD133+ cells (EAM d21) pre-treated for 3 days without (control, black) or with 10 ng/mL M-CSF (+M-CSF
d-3, hatch), washed and stimulated with 10 ng/mL TGF-b for 14 days. Relative mRNA levels of myofibroblast-specific genes (C, n ¼ 5) and represen-
tative immunofluorescence and quantification analysis of aSMA (D, top) and fibronectin (D, bottom) are shown (n ¼ 5). ***P, 0.001 (two-tailed
Student’s t-test vs. control), bar ¼ 20 mm.
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Next, we sorted heart-infiltrating CD133+/CD45+ cells from PBS-
and M-CSF-treated mice and found reduced mRNA levels of
myofibroblast-specific genes in the M-CSF-treated group (Figure 3E).
Furthermore, sorted heart-infiltrating CD133+/CD45+ cells from
both groups were plated and cultured in the presence of TGF-b for
10 days. CD133+/CD45+ cells isolated from the myocardium of
M-CSF-treated mice failed to differentiate into aSMA- and
fibronectin-expressing myofibroblasts (Figure 3F).
3.4 NOS2 controls M-CSF-dependent
macrophage differentiation of
heart-infiltrating CD1331 progenitors
F4/80hi macrophages derived from CD133+ progenitors up-regulate
NOS2 and produce nitric oxide. We, therefore, addressed the role
of NOS2 in the macrophage differentiation processes. Accordingly,
CD133+ progenitors were isolated at Day 21 after immunization
Figure 2 M-CSF treatment turns inflammatory CD133+ progenitors into F4/80+ macrophages in EAM. BALB/c mice were immunized with
aMyHC/CFA at Days 0 and 7, and treated with PBS or M-CSF between Days 21 and 29. (A) The quantification of F4/80+ macrophages in the myo-
cardium of PBS- (black) and M-CSF-treated (white) mice at Days 24 (n ¼ 6), 28 (n ¼ 5), and 40 (n ¼ 20). Immunopositive cells were quantified per
mm2 of heart tissue. (B) Flow cytometry analysis of CD133 and F4/80 on heart-infiltrating CD45+-gated cells (left) in EAM. The quantification of
CD133+ (left graph) and F4/80+ (right graph) cells gated on CD45+ infiltrates of PBS- (black) and M-CSF-treated (white) mice at Days 24
(n ¼ 5) and 28 (n ¼ 5) of EAM. (C–G) Flow cytometry analysis of M1 and M2 activation markers on heart-infiltrating CD45+/F4/80+-gated macro-
phages (left) in EAM. The mean fluorescence intensity (MFI) of membrane markers (CD16/32, CD206, CD301) and intracellular NOS2 expression
gated on inflammatory macrophages of PBS- (black) and M-CSF-treated (white) mice at Day 24 (n ¼ 10) of EAM. (–) isotype controls, (+) antigen-
specific antibodies. (H ) Overlay of phase contrast (left and middle) or F4/80 expression (right, red) with E. coli bacteria (green) taken up in the phago-
cytosis assay of expanded heart-infiltrating CD133+ cells (isolated from heart at d21) stimulated with M-CSF for 1 (left) and 3 days (middle and right).
Bar ¼ 20 mm. ns P . 0.05, *P, 0.05, **P, 0.01, ***P, 0.001 (two-tailed Student’s t-test).
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from inflamed hearts of wild-type or Nos22/2 mice and cultivated in
the presence of M-CSF. Nos22/2 CD133+ progenitors showed
reduced F4/80 and CD14 expression and were functionally impaired
as indicated by reduced E. coli phagocytosis (Figure 4A and E). To
determine whether macrophage differentiation was mediated by
NOS activity, CD133+ progenitors isolated from inflamed hearts of
BALB/c mice were cultured for 3 days in the presence of M-CSF
with or without L-NAME, a non-specific NOS inhibitor. Cells cultured
Figure 3 M-CSF inhibits myofibroblast lineage differentiation of inflammatory CD133+ in EAM. (A) Representative flow cytometry analysis of
CD133+ and F4/80 (right) gated on heart-infiltrating CD45+ cells (left) at Day 24 of EAM. Numbers indicate the percentage of positive cells in
the adjacent gates. (B) Heart-infiltrating CD45+/CD133+/F4/802 (white) and CD45+/CD133+/F4/80hi (black) cells were FACS sorted from
myocarditis-positive hearts at Day 24 of EAM. Relative mRNA levels of myofibroblast-specific genes are shown for one out of two independent
experiments (n ¼ 5). (C) Representative flow cytometry analysis of CD133 and F4/80 gated on heart-infiltrating CD45+/CD133+ progenitor cells
(left) of PBS- (+PBS) and M-CSF-treated (+M-CSF) mice at Day 24 of EAM. Staining with anti-CD45 and anit-CD133 and IgG control to anti-F4/
80 antibodies (IgG control) was used to set the gates. Numbers indicate the percentage of positive cells in the adjacent gates. (D) The quantification
of F4/80hi (left) and F4/802 (right) cells gated of CD45+/CD133+ progenitor cells (gated as shown in C) of PBS- (black) and M-CSF-treated (white)
mice at Day 24 of EAM. (E and F) Heart-infiltrating CD45+/CD133+ cells were FACSorted from myocarditis-positive hearts at Day 24 of EAM from
control PBS treated (black, +PBS) or M-CSF treated (white, +M-CSF). A relative mRNA level of myofibroblast-specific genes of sorted cells is shown
(E, n ¼ 5). In addition, sorted cells were plated and stimulated with 10 ng/mL TGF-b for 10 days. Representative immunofluorescence and quantifi-
cation analysis of aSMA (F, top) and fibronectin (F, bottom) are shown (n ¼ 5). Bar ¼ 20 mm, ns P. 0.05, *P, 0.05, **P, 0.01, ***P, 0.001 (two-
tailed Student’s t-test).
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with L-NAME showed significantly reduced E. coli phagocytosis
(Figure 4F) and reduced nitric oxide levels (Figure 4G).
3.5 M-CSF treatment prevents cardiac
fibrosis and left ventricular dysfunction
in EAM
M-CSF prevents TGF-b-mediated myofibroblast differentiation and
promotes the formation of macrophages from inflammatory
CD133+ progenitors. Given that CD133+ progenitors represent
the major source for myofibroblasts in EAM, we addressed whether
M-CSF treatment reduces fibrogenesis in the post-inflammatory
heart. Accordingly, we treated aMyHC/CFA-immunized mice with
M-CSF between Days 21–29 or 40–48 of EAM, and analysed the
hearts at Days 40 and 60, respectively (Supplementary material
online, Figure S3A). As illustrated in the Figure 5, M-CSF treatment
completely prevented accumulation of fibroblasts in the post-
inflammatory heart (Figure 5A–C; Supplementary material online,
Figure S4B). Of note, M-CSF treatment failed to attenuate fibrosis
when delivered between Days 40 and 48 (Figure 5A). These findings
suggest that M-CSF treatment prevented the fibrotic process, but
did not revert already established cardiac fibrosis.
Relapses of inflammatory cells are quite common in autoimmune
diseases. In BALB/c mice, we observed spontaneous inflammatory
relapses 40 days after the first immunization (Figure 5D and E).
During relapses, CD45+ inflammatory cells were mainly detected in
the pericardium and largely represented CD3+ T lymphocytes
(Figure 5D and E, Supplementary material online, Figure S3C). Interest-
ingly, M-CSF treatment between Days 21 and 29 inhibited relapses in
aMyHC/CFA-immunized mice as reflected by reduced numbers of
CD45+ and CD3+ T cells in the myocardium at Day 40 (Figure 5D
and E; Supplementary material online, Figure S3C).
Figure 4 NOS2 is required for M-CSF-dependent macrophage lineage differentiation from CD133+ progenitors. (A–E) Expanded heart-infiltrating
CD133+ cells (EAM d21) from wild-type BALB/c and Nos22/2 mice were stimulated with 10 ng/mL M-CSF for 3 days. (A) Representative flow cyto-
metry analysis of expanded cells using anti-CD133 (right) and IgG control (left) antibodies. Numbers indicate the percentage of positive cells in the
adjacent gates. Representative histogram analysis of macrophage-specific antigens F4/80 (B), CD11b (C), CD14 (D), and E. coli bacteria taken up in the
phagocytosis assay (E) on CD133+ cells (gated as shown in A). Isotype controls are displayed in grey. Numbers in histograms indicate mean fluor-
escence intensity (MFI). Bar graphs show quantification of the respective analyses for wild-type (black) and Nos22/2 (hatch) cells. n ¼ 5, (–) isotype
controls, (+) antigen-specific antibodies or E. coli. (F) Expanded heart-infiltrating CD133+ cells (EAM d21) from BALB/c (wild-type) mice were sti-
mulated with 10 ng/mL M-CSF for 3 days in the absence (control) or presence of 2 mM L-NAME (+L-NAME). Representative histogram analysis of
E. coli bacteria uptake by CD133+ cells (gated as shown in A). Controls without E. coli are displayed in grey. Numbers in histograms indicate MFI. Bar
graphs show the quantification of the respective analyses in the absence (white) or presence of L-NAME (grey). n ¼ 5, (2) control, (+) E. coli.
(G) Nitrite levels in supernatants of cultures stimulated with 0.1 mg/mL LPS for 24 h. n ¼ 4. ns P. 0.05, *P, 0.05, **P, 0.01, ***P, 0.001 (two-
tailed Student’s t-test).
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Cardiac fibrosis parallels both, diastolic dysfunction, and reduced
cardiac contractility. Not all immunized mice develop severe myocar-
ditis. Consequently, the extent of post-inflammatory fibrosis varies in
the EAM model. In our series, 11 out of 20 aMyHC/CFA-immunized
BALB/c mice showed substantial fibrosis (.2% of total heart area) on
Day 40. At this time point, echocardiography revealed reduced ejec-
tion fraction and fractional shortening in mice with significant fibrosis
(Figure 5F). In addition, the extent of fibrosis correlated with increased
mass, systolic and diastolic volume, and isovolumetric contraction
time of the left ventricle (Supplementary material online, Figure
S5A). Echocardiography of aMyHC/CFA-immunized and M-CSF-
treated mice showed unaffected cardiac function at Day 40
(Figure 5F, Supplementary material online, Figure S5E).
Next, we immunized Nos22/2 mice with aMyHC/CFA and treated
with M-CSF or PBS between Days 21 and 29. aMyHC/CFA immuniza-
tion resulted in myocarditis in Nos22/2 mice (not shown), but M-CSF
treatment failed to affect fibrosis and heart functions during the post-
inflammatory phase of EAM in Nos22/2 mice (Figure 6A, Supplemen-
tary material online, Figure S6). Similar results were observed if mice
were M-CSF treated between Days 14 and 22 (not shown). M-CSF
Figure 5 M-CSF treatment attenuates myocardial fibrosis and prevents heart failure in EAM. BALB/c mice were immunized at Days 0 and 7 with
aMyHC/CFA and injected either with PBS (black) or M-CSF between Days 21 and 29 (white) or days 40 and 48 (grey). (A) Fibrosis was evaluated in
heart sections at Days 24 (n ¼ 10), 28 (n ¼ 10), 40 (n ¼ 20), and 60 (n ¼ 6–8). The degree of fibrosis was analysed by Masson’s trichrome staining
and calculated as the percentage of the fibrotic area in heart sections. (B and C) The representative microphotographs of the myocardial tissue (d60)
following PBS (B) or M-CSF (C) treatment between Days 21 and 29 stained with Masson’s trichrome. Bar ¼ 100 mm. P-values were computed using
the two-tailed Student’s t-test (A, d24, d28, and d40), one-way ANOVA (A, d60). (D–E) The quantification of CD45+ cells (defining all inflammatory
infiltrates, D) and CD3+ cells (defining T lymphocytes, E) within the myocardium during EAM at Days 24 (n ¼ 10), 28 (n ¼ 10), 40 (n ¼ 20), and 60
(n ¼ 6–8) after the first immunization. Immunopositive cells were quantified per mm2 of heart tissue. (F ) Echocardiographic parameters of healthy,
untreated BALB/c mice (white) in comparison with aMyHC/CFA-immunized mice with ,2% myocardial fibrosis (hatch, n ¼ 9), .2% myocardial
fibrosis (black, n ¼ 11), and aMyHC/CFA-immunized mice treated with M-CSF at Days 21–29 (grey, n ¼ 20). P-values were computed using correl-
ation analysis (F ) and the one-way ANOVA (A, D, and E). *P, 0.05, **P, 0.01, ***P, 0.001 for the respective group vs. healthy controls (white)
calculated with the Bonferroni post hoc test.
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treatment of Nos22/2 mice failed to increase the numbers of F4/80+
macrophages and CD133+ cells in the myocardium at Days 24 and 40
of EAM (Figure 6A–C ). We also observed no differences in F4/80 ex-
pression on inflammatory CD133+/CD45+ progenitors (not shown)
and in the expression of M1/M2 markers on heart-infiltrating
F4/80+/CD45+ macrophages between M-CSF- and PBS-treated
Nos22/2 mice (Figure 6D).
4. Discussion
We previously reported that in the EAM model post-inflammatory
pathogenic myofibroblasts mainly originate from heart-infiltrating
CD133+ progenitor cells.6 In line with our previous findings, herein
we demonstrate that M-CSF controls the formation of anti-
inflammatory macrophages from inflammatory CD133+ progenitors
and prevents TGF-b-mediated differentiation into pathogenic myofi-
broblasts. Thus, our data suggest that in myocarditis, a significant
pool of cells infiltrating the myocardium at the peak of disease repre-
sent non-committed progenitors.
From a clinical perspective, it is important that the differentiation
fate of multipotent, non-committed precursor cells infiltrating the
myocardium, can be modulated via specific cytokine signalling in a
controlled fashion. M-CSF is a key cytokine guiding macrophage differ-
entiation in vitro8 and in vivo.18 In EAM, M-CSF treatment up-regulated
F4/80 expression on CD133+ inflammatory progenitors promoting
macrophage differentiation. In untreated mice, however, heart-
infiltrating CD133+ progenitors spontaneously differentiate into
pathogenic myofibroblasts. To our knowledge, this is the first
report describing the change of in vivo fate of inflammatory progeni-
tors naturally present in the inflamed organ. So far, it has been
Figure 6 M-CSF treatment fails to reduce fibrosis in Nos22/2 mice. Nos22/2 mice were immunized at Days 0 and 7 with aMyHC/CFA and treated
with PBS or M-CSF between Days 21 and 29. (A and B) The quantification of fibrosis and F4/80+ macrophages in the myocardium of PBS- (black) and
M-CSF-treated (white) Nos22/2 mice at Days 24 (A, n ¼ 5) and 40 (B, n ¼ 10) of EAM. F4/80+ cells were quantified per mm2 of heart tissue, and the
degree of fibrosis was analysed by Masson’s trichrome staining. (C ) Representative histograms of CD133 expression gated on heart-infiltrating CD45+
inflammatory cells (left) of PBS- (+PBS) and M-CSF-treated (+M-CSF) Nos22/2 mice at Day 24 of EAM. Isotype controls are displayed in grey.
Numbers indicate the percentage of positive cells in the presented histograms. Bar graphs show the quantification of CD133+ and F4/80+ gated
on CD45+ cells of PBS- (black) and M-CSF-treated (white) Nos22/2 mice (n ¼ 5). (D) Flow cytometry analysis of M1 and M2 activation markers
in EAM. The quantification of the mean fluorescence intensity (MFI) of membrane macrophage activation markers gated on heart-infiltrating
CD45+/F4/80+-gated macrophages (left) of PBS- (black) and M-CSF-treated (white) Nos22/2 mice at Day 24 of EAM (n ¼ 5). (2) isotype controls,
(+) antigen-specific antibodies, ns P. 0.05 (two-tailed Student’s t-test).
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described that M-CSF treatment improved cardiac function in a viral
model of myocarditis,16 after myocardial infarction14,15,19 and in the
ischaemia-reperfusion model.20 Similar to our findings, M-CSF treat-
ment promoted monocyte/macrophage accumulation in the heart
after myocardial infarction14,15 or virus inoculation16.
Myocardial fibrosis plays a dual role in remodelling after cardiac
injury. On one hand, it is a pre-requisite for wound healing, as in
the case of ischaemic injuries, for example. On the other hand, it con-
tributes to ventricular stiffening and typical pathological remodelling in
heart failure. Our previous and current data clearly show that exces-
sive cardiac fibrosis parallels impaired cardiac function in EAM.17 Thus,
preserved left ventricular function in M-CSF-treated mice results pri-
marily from reduced myofibroblast differentiation, rather than pro-
tective macrophage activity. We propose that the conversion of
inflammatory progenitors into functional macrophages, instead of
myofibroblasts, represents a key mechanism explaining reduced fibro-
genesis upon M-CSF treatment. However, we cannot rule out that
M-CSF also activates other pathways inhibiting myocardial fibrogen-
esis. For example, M-CSF may protect cardiomyocytes from H2O2-
induced death.20 Moreover, M-CSF could affect extracellular matrix
composition and levels of matrix metalloproteinases and cytokines/
chemokines, which drastically alter the myocardial microenvironment.
Nevertheless, we can exclude direct M-CSF-mediated effects on
cardiac fibroblasts, because upon M-CSF treatment during the late
post-inflammatory phase of the EAM (Days 40–48), the fibrosis
was not reverted.
It has been proposed that differential macrophage activation defines
protective and pathogenic functions. Accordingly, adoptive transfer of
M1 macrophages promoted histological disease scores, whereas injec-
tion of M2 macrophages was largely protective in Coxackievirus-
induced myocarditis.9 Also most heart-infiltrating macrophages were
classified as M2 macrophages expressing mannose receptor and Gr-1
in aMyHC/CFA- and Coxackievirus-induced myocarditis.7,21
However, macrophages expressing M1 marker NOS2 have been iden-
tified in myocarditis as well.22 We critically analysed macrophages in the
myocardium after the peak of disease, during the post-inflammatory
phase of EAM, and detected both, M1- and M2-specific markers. We
were, however, unable to clearly delineate two distinct activation
states. We assume that during EAM, heart-infiltrating macrophages
were activated classically (M1) and alternatively (M2) at the same
time. In fact, it is well known that T cells and other heart-infiltrating
cells massively produce both M1-activating IFN-g as well as
M2-activating IL-4 and IL-13.7 Importantly, M-CSF treatment did not
affect the expression of M1 and M2 markers except of NOS2.
M-CSF-induced macrophage accumulation in the post-inflammatory
heart was not pathogenic in our model, because resolution of inflamma-
tion, defined by the extent of inflammatory cells was clearly M-CSF in-
dependent. Moreover, M-CSF-induced macrophages showed strong
immunosuppressive activity in vitro and in vivo. We believe that the accu-
mulation of the immunosuppressive macrophages in M-CSF-treated
mice protected from spontaneous T cell relapse. Nevertheless, we
cannot, entirely rule out that M-CSF also mediates protective effects
by acting on other target cells.
We previously found that M-CSF-induced CD11b+ monocytes
prevented EAM development and suppressed CD4+ T cell prolifer-
ation in a nitric oxide-dependent manner.23 M-CSF treatment pro-
moted inflammatory macrophages expressing NOS2 in EAM, We,
therefore, hypothesized that macrophage-produced nitric oxide
might control both; T cell-mediated early inflammation as well as
post-inflammatory fibrosis in EAM. Indeed, mice lacking NOS2 or
treated with nitric oxide inhibitors showed enhanced cardiac inflam-
mation and fibrotic lesions in a model of Coxackievirus-induced myo-
carditis.24,25 Similarly, Nos22/2 mice also develop more severe
myocarditis in the EAM model (Kania et al., unpublished observa-
tions). Nevertheless, we observed spontaneous resolution of inflam-
mation in Nos22/2 mice, suggesting that NOS2 is not critically
involved in the resolution of inflammation in the EAM model. Surpris-
ingly, treatment of Nos22/2 mice with M-CSF failed to turn CD133+
progenitors into macrophages and to prevent fibrosis development.
Furthermore, we showed that Nos22/2 CD133+ progenitors stimu-
lated with M-CSF failed to generate functional macrophages. These
results suggested that NOS2 was required for M-CSF-induced macro-
phage differentiation and maturation. Accordingly, NOS2 has been
reported to control differentiation of human monoblasts.26 Regulation
of gene expressions by nitric oxide can explain requirement of NOS2
in this differentiation processes.27 At this stage, we cannot, however,
exclude that in Nos22/2 mice, heart-infiltrating CD133+ progenitors
are committed towards the fibroblast phenotype due to an alerted
cytokine expression profile in the myocardium. Based on our findings,
we can assume that M-CSF stimulates nitric oxide production that, in
turn, promotes macrophage differentiation of inflammatory
progenitors.
In summary, our data demonstrate that a single haematopoietic
cytokine, such as M-CSF can modulate the in vivo fate of inflammatory
CD133+ progenitors in a way to promote their differentiation into
macrophages instead of myofibroblasts in the post-inflammatory
phase of the EAM. Furthermore, our data suggest that mature inflam-
matory macrophages, in contrast to progenitor-derived fibroblasts, do
not promote heart failure after acute myocarditis. These findings are
in line with the clinical observation that fulminant myocarditis implies
an excellent long-term prognosis, whereas subacute myocarditis
usually progresses to end-stage heart failure.28
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Supplementary material is available at Cardiovascular Research online.
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